FierceBiotech5d
Sanofi takes $250M hit after gamble on J&J E. coli vaccine ends in phase 3 failure
A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, ...
STAT12h
Pharmalittle: We’re reading about the impact of HHS firings, a GSK vaccine approval, and more
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
J&J, Sanofi stop E.coli vaccine trial due to low effectiveness
Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...
Johnson & Johnson halts late-stage E.coli vaccine trial after poor results
Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary ...
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal year in vaccine race
CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies and vaccines with a market ...
Sanofi Ends Trial for E. Coli Shot and Takes a $250 Million Hit
Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an ...
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
Sanofi SA (NASDAQ:SNY) and Johnson & Johnson (NYSE:JNJ) have discontinued the E.mbrace phase 3 study evaluating a vaccine ...
Sanofi to take $250M charge on study failure for E. coli vaccine
The French drugmaker said the vaccine it agreed to develop with Johnson & Johnson a year ago was “not sufficiently effective.
pharmaphorum5d
Sanofi, J&J abandon trial of E coli vaccine after poor data
Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial.
The Pharma Letter5d
Sanofi/J&J drop development of E. coli vaccine
French pharma major Sanofi’s saw its shares edge up 1% by early afternoon, despite announcing a disappointment for a vaccine ...
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical studyIndependent interim analysis of the E.mbrace phase 3 study finds that ...